The proteasome inhibitor PS-341 (bortezomib or Velcade), an approved drug for treatment of patients with multiple myeloma, is currently being tested in clinical trials against various malignancies, including lung cancer. Preclinical studies have shown that PS-341 induces apoptosis and enhances tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–induced apoptosis in human cancer cell...

Proteasome inhibitor PS-341 (also known as bortezomib) and histone deacetylase (HDAC) inhibitors have emerged as novel therapeutic agents for a variety of malignancies. In this study, we examined whether PS-341 and the HDAC inhibitor trichostatin A (TSA) induced apoptosis in head and neck squamous cell carcinoma (HNSCC), a common and lethal malignancy. We found that, although TSA treatment alon...

INTRODUCTION The aim of this study was to evaluate the epidemiologic profile of patients and difficulties of patients referred by basic health units (UBS) or other hospitals, outpatient screening of the Division of Nephrology, Hospital São Paulo (UNIFESP) for evaluation and treatment kidney disease. METHODS From February to September 2009, has been evaluated 341 patients referred from UBS in ...

BACKGROUND Plasmodium vivax malaria is an acute debilitating illness characterized by recurrent paroxysmal fever and relapses from hypnozoites in the liver. Although a few studies reported clinical characteristics of vivax malaria in civilians after reemergence in the Republic of Korea, only a small group of patients was analyzed. MATERIALS AND METHODS We retrospectively reviewed the medical ...

Amaç: Ailesel Akdeniz Ateşi (AAA), kökenli popülasyonlarda sıklıkla görülen otoinflamatuvar bir hastalıktır. MEFV genindeki mutasyonların, FMF'nin gelişiminin temelini oluşturduğu saptanmıştır. Bu nedenle, bu çalışmada mutasyonlarının tespitinde yeni nesil dizileme ve polimeraz zincir reaksiyonu yöntemlerinin olası farklılıklarını araştırmayı amaçladık. Gereç yöntem: çalışma 01.08.2018 - 12.03....

Proteasome inhibition following DNA damage results in the synergistic induction of apoptosis via a nuclear factor-kappaB-independent mechanism. In this study, we identify the role of p53 in mediating apoptosis by the sequence-specific treatment involving the DNA-damaging, topoisomerase I-targeting drug SN-38 followed by the proteasome inhibitor PS-341 (SN-38-->PS-341). The p53-dependent sensiti...

Proteasome inhibition following DNA damage results in the synergistic induction of apoptosis via a nuclear factor-KB– independent mechanism. In this study, we identify the role of p53 in mediating apoptosis by the sequence-specific treatment involving the DNA-damaging, topoisomerase I–targeting drug SN-38 followed by the proteasome inhibitor PS-341 (SN-38!PS-341). The p53-dependent sensitizatio...

BACKGROUND PS-341, a selective inhibitor of the proteasome, currently is under evaluation as an anticancer agent in multiple phase I clinical trials. In animal-model studies, PS-341 was rapidly removed from the vascular compartment and distributed widely, quickly approaching the limits of detection. An accurate pharmacodynamic assay has been developed as an alternative or complement to pharmaco...

Th is paper reports research on service branding carried out on the prestigious Norwegian Coastal Voyage, or Hurtigruten, which is its brand name. Th e primary research instrument employed in the research was semi-structured in-depth interviews with managers and service personnel previously and presently employed by the shipping line Hurtigruten ASA. Th e paper shows that a set of factors infl ...